Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance
Source abstract
Abstract
At present, combined therapy has become an effective strategy for the treatment of cancer. Co-delivery of the chemotherapeutic drugs and siRNA can more effectively inhibit tumor growth by nano drug delivery systems (NDDSs). Here, we prepared and evaluated a multifunctional envelope-type nano device (MEND). This MEND was a kind of composite lipid-nanoparticles possessing both the properties of liposomes and nanoparticles. In this study, an acid-cleavable ketal containing poly (β-amino ester) (KPAE) was used to bind siBCL-2 and the KPAE/siBCL-2 complexes were further coated by epirubicin (EPI) containing lipid to form EPI/siBCL-2 dual loaded lipid-nanoparticles. The results showed that the average size of EPI/siBCL-2-MEND was about 120 nm, and the average zeta potential was about 41 mV. The encapsulation efficiency (EE) of EPI and siBCL-2 was 86.13% and 97.07%, respectively. EPI/siBCL-2 dual loaded lipid-nanoparticles showed enhanced inhibition efficiency than individual EPI-loaded liposomes on HepG2 cells by MTT assay. Moreover, western blot experiment indicated co-delivery of EPI/siBCL-2 can significantly down-regulate the expression of P-glycoprotein (P-gp), while free EPI and EPI-loaded liposomes up-regulated it. Therefore, the strategy of co-delivering EPI and siBCL-2 simultaneously by lipid-nanoparticles showed promising potential in reversing multidrug resistance of tumor cells.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Qingdao University, Qingdao, China;
Department of Neurology, Shengli Hospital, Dongying, China
Funding
Shandong science and technology development projects · National Natural Science Fund Project in 2016
References (33)
Show source-provided references
1. 10.1016/j.ijpharm.2014.08.01910.1016/j.ijpharm.2014.08.019 ↗
2. 10.1021/nn103349h10.1021/nn103349h ↗
3. 10.1016/j.jconrel.2015.08.03210.1016/j.jconrel.2015.08.032 ↗
4. 10.1002/adhm.20150082610.1002/adhm.201500826 ↗
5. 10.1038/sj.cgt.770093110.1038/sj.cgt.7700931 ↗
6. 10.1038/nmat325310.1038/nmat3253 ↗
7. 10.1007/s10565-009-9141-y10.1007/s10565-009-9141-y ↗
8. Mastrobattista E · Nat Rev · 2006 · 5 · 115
9. 10.1016/j.jconrel.2007.06.01810.1016/j.jconrel.2007.06.018 ↗
10. 10.1016/j.addr.2007.10.00710.1016/j.addr.2007.10.007 ↗
11. 10.1021/bm801199z10.1021/bm801199z ↗
12. 10.1021/acs.nanolett.6b0291510.1021/acs.nanolett.6b02915 ↗
13. 10.1021/acsami.5b1178910.1021/acsami.5b11789 ↗
14. 10.1039/B914063H10.1039/B914063H ↗
15. 10.1021/bm100309y10.1021/bm100309y ↗
16. 10.1016/j.biomaterials.2008.02.01810.1016/j.biomaterials.2008.02.018 ↗
17. 10.1038/srep3522310.1038/srep35223 ↗
18. 10.1016/j.colsurfb.2016.06.03410.1016/j.colsurfb.2016.06.034 ↗
19. 10.3892/or.2016.463210.3892/or.2016.4632 ↗
20. 10.1186/2193-1801-2-63910.1186/2193-1801-2-639 ↗
21. 10.1038/sj.gt.330284310.1038/sj.gt.3302843 ↗
22. 10.18632/oncotarget.624310.18632/oncotarget.6243 ↗
23. 10.3892/ijo.2015.317410.3892/ijo.2015.3174 ↗
24. 10.1016/j.ijpharm.2013.06.02110.1016/j.ijpharm.2013.06.021 ↗
25. 10.1021/nn100968e10.1021/nn100968e ↗
26. 10.1016/j.ijpharm.2014.10.01410.1016/j.ijpharm.2014.10.014 ↗
27. 10.1016/j.jconrel.2014.10.00510.1016/j.jconrel.2014.10.005 ↗
28. 10.1016/j.biomaterials.2016.06.00710.1016/j.biomaterials.2016.06.007 ↗
29. 10.1016/j.jconrel.2016.02.02110.1016/j.jconrel.2016.02.021 ↗
30. Attia ABE · Small · 2014 · 10 · 428110.1002/smll.201401295 ↗
31. 10.1016/j.ijpharm.2015.10.02810.1016/j.ijpharm.2015.10.028 ↗
32. Gabizon A · Cancer Res · 1994 · 54 · 987
33. 10.1016/j.jconrel.2014.10.00110.1016/j.jconrel.2014.10.001 ↗